Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran ( lonvo-z ) in Patients with Hereditary Angioedema ( HAE ) at the European Academy of Allergy and Clinical Immunology Congress
CAMBRIDGE, Mass., June 15, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing ...
IBTA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ibotta, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm - IBTA - Ibotta ( NYSE:IBTA )
NEW YORK, June 15, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc.
TradFi's deep liquidity issue is crypto's silent structural risk
Despite crypto's rapid growth and decentralized ideals, its liquidity remains fragmented and fragile - mirroring traditional finance's hidden risks and exposing the market to sudden shocks when sentiment shifts.
What Are Internet Capital Markets? Why Companies Are Launching Meme Coins
Traditional stocks are old news. Now, companies are launching meme coins to fund or market their businesses.
Dupixent® ( dupilumab ) Demonstrated Superiority Over Xolair® ( Omalizumab ) in Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP ) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints ...
Dupixent® ( dupilumab ) Demonstrated Superiority Over Xolair® ( Omalizumab ) in Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP ) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y. and PARIS, June 15, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps ( CRSwNP ) and coexisting asthma.
Press Release: EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study ...
Press Release: EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - Regeneron Pharmaceuticals ( NASDAQ:REGN )
EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Investors Urged to Contact Levi & Korsinsky for Information Before August 1, 2025 - Fortrea Holdings Inc. ( FTRE )
Investors Urged to Contact Levi & Korsinsky for Information Before August 1, 2025 - Fortrea Holdings Inc. ...
Lost Money on Iovance Biotherapeutics, Inc. ( IOVA ) ? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action ...
